Search Result

Results for "

PARP1+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (22) Bcl-2 Family (2) BCRP (1) c-Met/HGFR (1) Cadherin (1) Caspase (6) CDK (2) Deubiquitinase (2) DNA/RNA Synthesis (6) EGFR (2) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (1) Glutathione Peroxidase (1) IFNAR (1) Interleukin Related (1) Microtubule/Tubulin (1) NF-κB (2) PARP (84) Poly(ADP-ribose) Glycohydrolase (PARG) (1) PPAR (1) Pyroptosis (2) Reactive Oxygen Species (ROS) (6) Reference Standards (3) STING (1) TGF-β Receptor (1) Topoisomerase (1)
By Research Areas:	Cancer (81) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (6) Neurological Disease (9)

By Targets:

Apoptosis (22)

Bcl-2 Family (2)

BCRP (1)

c-Met/HGFR (1)

Cadherin (1)

Caspase (6)

CDK (2)

Deubiquitinase (2)

DNA/RNA Synthesis (6)

EGFR (2)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

ERK (1)

Glutathione Peroxidase (1)

IFNAR (1)

Interleukin Related (1)

Microtubule/Tubulin (1)

NF-κB (2)

PARP (84)

Poly(ADP-ribose) Glycohydrolase (PARG) (1)

PPAR (1)

Pyroptosis (2)

Reactive Oxygen Species (ROS) (6)

Reference Standards (3)

STING (1)

TGF-β Receptor (1)

Topoisomerase (1)

By Research Areas:

Cancer (81)

Cardiovascular Disease (2)

Infection (2)

Inflammation/Immunology (6)

Neurological Disease (9)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114778

Fluzoparib 4 Publications Verification SHR3162; Fuzuloparib	PARP	Cancer
Fluzoparib (SHR3162) is a potent and orally active *PARP1* inhibitor (IC₅₀=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research ^[1].

HY-145471

KSQ-4279 1 Publications Verification USP1-IN-1	Deubiquitinase PARP	Cancer
KSQ-4279 (USP1-IN-1) is a potent *USP1* inhibitor and a selective *PARP1* inhibitor. KSQ-4279 is promising for research of cancers ^[1].

HY-145804

Palacaparib 1 Publications Verification AZD-9574	PPAR	Neurological Disease Cancer
AZD-9574 is a potent and brain penetrant *PARP1* inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD ⁺?breast cancer and advanced solid malignancies research ^[1].

HY-12032

AG14361 Maximum Cited Publications 7 Publications Verification	PARP	Cancer
AG14361 is a potent *PARP-1* inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC₅₀s are 29 nM and 14 nM, respectively.

HY-113352

7-Methylguanine	Endogenous Metabolite PARP	Cancer
7-Methylguanine is an orally active and competitive *PARP-1* inhibitor with a K_i value of 61 μM. 7-Methylguanine is a metabolite of nucleic acids. 7-Methylguanine has anticancer activity against uterine sarcoma and colon adenocarcinoma. 7-Methylguanine is used as a probe for protein-DNA interactions ^[1] .

HY-114869

DPQ 3 Publications Verification	PARP	Neurological Disease Cancer
DPQ is a selective *PARP-1* inhibitor that blocks PARP-1-mediated DNA damage repair and NAD ⁺/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases ^[1] .

HY-171007

IRF1-IN-2 1 Publications Verification	Caspase PARP Pyroptosis Interleukin Related Glutathione Peroxidase IFNAR	Infection Inflammation/Immunology
IRF1-IN-2 (Compound I-19) is an *IRF1* inhibitor. IRF1-IN-2 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-2 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, *IL-1* and *PARP1*; inhibits the Pho of TKB1, upregulates GPX4 and downregulates FACL4). IRF1-IN-2 has a protective effect on ionizing radiation-induced inflammatory skin injury ^[1].

HY-10619D

Niraparib (R-enantiomer) MK 4827 (R-enantiomer)	PARP	Cancer
Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent *PARP1* inhibitor with IC₅₀ of 2.4 nM.

HY-18954

NMS-P118 3 Publications Verification	PARP	Cancer
NMS-P118 is a potent, orally available, and highly selective *PARP-1* Inhibitor for cancer therapy.

HY-16106A

(8R,9S)-Talazoparib (8R,9S)-BMN-673; (8R,9S)-LT-673	PARP	Cancer
(8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an *PARP1* inhibitor, with an IC₅₀ of 144 nM ^[1].

HY-164926

PARP1-IN-33	PARP	Neurological Disease
PARP1-IN-33 (Example 6) is a *PARP1* inhibitor (IC₅₀: 0.41 nM). PARP1-IN-33 has retinal cytoprotective effect, with an EC₅₀ of 0.02 nM (inhibition on MTS activity of H₂O₂ induced human retinal pigment epithelial cell) ^[1].

HY-W006566

5-AIQ 5-Aminoisoquinolin-1-one	PARP	Cancer
5-AIQ (5-Aminoisoquinolin-1-one) is a *PARP-1* inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver ^[1] .

HY-108632

BYK204165 1 Publications Verification	PARP	Cancer
BYK204165 is a potent and selective *PARP1* inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC₅₀ of 7.35 (pK_i=7.05), and murine PARP-2 (mPARP-2) with a pIC₅₀ of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1 ^[1].

HY-147027

PARP-1-IN-2	PARP Caspase Apoptosis	Neurological Disease Inflammation/Immunology Cancer
PARP-1-IN-2 (compound 11g) is a potent *PARP1* inhibitor, with an IC₅₀ of 149 nM, and ADME prediction indicates it has high blood-brain barrier permeability. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis ^[1].

HY-145471A

KSQ-4279 gentisate 1 Publications Verification	Deubiquitinase PARP	Cancer
KSQ-4279 (gentisate) (Compound Formula I) is a potent *USP1* inhibitor and a selective *PARP1* inhibitor. KSQ-4279 (gentisate) is promising for research of cancers ^[1].

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer ^[1].

HY-136489

KU-0058948	PARP Apoptosis	Cancer
KU-0058948 is a specific and potent *PARP1* inhibitor with an IC₅₀ of 3.4 nM. KU-0058948 induces cell cycle arrest and apoptosis of primary myeloid leukemic cells and myeloid leukemic cell lines ^[1] .

HY-147886

PARP1-IN-11 1 Publications Verification	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 ^[1].

HY-W156961

LS-75	PARP	Neurological Disease
LS-75 is a *PARP-1* inhibitor with blood-brain permeability and IC₅₀ value of 18 μM. LS-75 has neuroprotective activity ^[1].

HY-149348

DiPT-4	Topoisomerase PARP Apoptosis	Cancer
DiPT-4 is a dual *TOP1/PARP1* inhibitor that induces massive DNA double-strand breaks (DSBs), cell cycle arrest, and apoptosis in cancer cells. DiPT-4 has the potential to overcome cancer drug resistance ^[1].

HY-179406

PARP1-IN-49	PARP DNA/RNA Synthesis Reactive Oxygen Species (ROS) Apoptosis	Cancer
PARP1-IN-49 is a selective *PARP1* inhibitor with an IC₅₀ of 23.56 nM and a K_d of 17.78 nM. PARP1-IN-49 shows a selectivity for PARP1 over PARP2. PARP1-IN-49 leads to the induction of DNA damage, cell cycle arrest, and apoptosis. PARP1-IN-49 also increases intracellular ROS levels and inhibits cell migration. PARP1-IN-49 can be used for the research of breast cancer and ovarian cancer ^[1].

HY-128599

NMS-P515	PARP	Cancer
NMS-P515 is a potent, orally active and stereospecific *PARP-1* inhibitor, with a K_d of 16 nM and an IC₅₀ of 27 nM (in Hela cells). Anti-tumor activity ^[1].

HY-175471

PARP1-IN-42	PARP	Cancer
PARP1-IN-42 (Example 43 cis-a) is a *PARP1* inhibitor with IC₅₀ <10 nM. PARP1-IN-42 can be used in cancer research ^[1].

HY-34386

6(5H)-Phenanthridinone	PARP	Inflammation/Immunology Cancer
6(5H)-Phenanthridinone is a potent *PARP-1* inhibitor and immunomodulator. 6(5H)-Phenanthridinone inhibits cell proliferation and can be used in cancer research ^[1].

HY-132297

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer ^[1].

HY-136489A

KU-0058948 hydrochloride	PARP Apoptosis	Cancer
KU-0058948 hydrochloride is a specific and potent *PARP1* inhibitor with an IC₅₀ of 3.4 nM. KU-0058948 hydrochloride induces cell cycle arrest and apoptosis of primary myeloid leukemic cells and myeloid leukemic cell lines ^[1] .

HY-132157

8-Chloroquinazolin-4-ol	PARP	Cancer
8-Chloroquinazolin-4-ol is a poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor with an IC₅₀ value of 5.65 μM. 8-Chloroquinazolin-4-ol can be used in cancer-related research ^[1].

HY-175482

PARP1-IN-43	PARP	Neurological Disease Cancer
PARP1-IN-43 (Compound 5350) is a blood-brain barrier (BBB) permeable *PARP1* inhibitor, with an IC₅₀ of 5 nM. PARP1-IN-43 can be used for the study of homologous recombination (HR)-deficient central nerve system (CNS) cancers ^[1].

HY-178100

PARP1-IN-45	PARP BCRP	Cancer
PARP1-IN-45 (Compound 15) is a *PARP1* inhibitor with an IC₅₀ of 17  nM. PARP1-IN-45 effectively stimulates ATPase activity of ABCG2. PARP1-IN-45 can be used for cancers like ovarian cancer research ^[1].

HY-169575

PARP1-IN-36	PARP	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
PARP1-IN-36 (compound 11) is a 4-carboxamido-isoindolinone derivative and a selective *PARP-1* inhibitor with a K_d < 0.01 μM. PARP1-IN-36 can be utilized in cancer, cardiovascular diseases, nervous system injury and inflammation research ^[1].

HY-144642

PARP-1-IN-1	PARP	Cancer
PARP-1-IN-1 is a high selective and orally active *PARP-1* inhibitor (IC₅₀=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model ^[1].

HY-149001

PARP1-IN-9	PARP	Cancer
PARP1-IN-9 (Compound 5c) is a PARP1 inhibitor with an IC₅₀ of 30.51 nM. PARP1-IN-9 induces cell apoptosis and shows anticancer activity. PARP1-IN-9 has higher potency than Olaparib (HY-10162) ^[1].

HY-W006566R

5-AIQ (Standard) 5-Aminoisoquinolin-1-one (Standard)	Reference Standards PARP	Cancer
5-AIQ (5-Aminoisoquinolin-1-one) is a PARP-1 inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver ^[1] .

HY-178468

PARP1-IN-47	PARP	Cancer
PARP1-IN-47 (Compound 35) is a highly selective *PARP1* inhibitor (IC₅₀ <100 nM). PARP1-IN-47 blocks poly(ADP-ribosyl)ation and disrupts DNA damage repair pathways to induce tumor cell apoptosis. PARP1-IN-47 is promising for research of solid tumors and hematological malignancies ^[1].

HY-N15380

4,4′-Secalonic acid D	PARP Reactive Oxygen Species (ROS) Caspase Apoptosis Pyroptosis	Cancer
4,4′-Secalonic acid D (Compound 12) is a *PARP1* inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting *PARP1*. 4,4′-Secalonic acid D has anti-tumor activity ^[1].

HY-10615

A-620223 1 Publications Verification	PARP	Cancer
A-620223 is a *PARP-1* inhibitor with a K_i of 8 nM against PARP-1 and EC₅₀ of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) (HY-17364) and in an MX-1 breast xenograph model in combination with Cisplatin (HY-17394). A-620223 can be used for the studies of melanoma and breast cancer ^[1].

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active *PARP-1* inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting *PARP-1* in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting *PARP-1* activity in cancer ^[1].

HY-175257

Theophylline-platinum(IV) prodrug-1	PARP Reactive Oxygen Species (ROS) Apoptosis NF-κB ERK Bcl-2 Family TGF-β Receptor EGFR Cadherin	Cancer
Theophylline-platinum(IV) prodrug-1 is a *PARP-1* inhibitor. Theophylline-platinum(IV) prodrug-1 enhances DNA damage, ROS production, mitochondrial dysfunction, apoptosis and S-phase arrest, along with reducing invasion and metastasis in cells. Theophylline-platinum(IV) prodrug-1 exhibits superior antitumor activity in the xenograft SKOV3-BRCA1-KD tumor model. Theophylline-platinum(IV) prodrug-1 can be used for the study of ovarian cancer ^[1].

HY-178178

PARP1-IN-46	PARP Reactive Oxygen Species (ROS) DNA/RNA Synthesis Apoptosis	Cancer
PARP1-IN-46 is a potent *PARP-1* inhibitor with an IC₅₀ of 2.4 nM. PARP1-IN-46 demonstrates remarkable anti-proliferative activity in both rat (C6) and human (U87MG) glioma cells. PARP1-IN-46 promotes PARP cleavage, triggers DNA damage, and increases ROS. PARP1-IN-46 effectively inhibits the migration, invasion and colony formation of glioma cells, and ultimately induces cell apoptosis. PARP1-IN-46 can be used to the study of glioma ^[1].

HY-178032

PARP1-IN-44	PARP Apoptosis Reactive Oxygen Species (ROS) DNA/RNA Synthesis STING	Cancer
PARP1-IN-44, an Olaparib (HY-10162) derivative, is an orally active *PARP1* inhibitor (IC₅₀ = 0.6 nM), and also inhibits *PARP2* (IC₅₀ = 1.0 nM) and *PARP7* (IC₅₀ = 7.5 nM). PARP1-IN-44 has selective antiproliferative activity against BRCA-deficient cancer cells with minimal toxicity to normal cells. PARP1-IN-44 induces G2/M phase arrest, promotes apoptosis, elevates ROS levels, disrupts mitochondrial membrane potential. PARP1-IN-44 suppresses PARylation while increasing γH2AX accumulation. PARP1-IN-44 activates the cGAS-STING pathway, upregulating IFN-β and CXCL10 expression. PARP1-IN-44 enhancing CD8+ T cell infiltration in a CT26 tumor mouse model, demonstrating robust in vivo antitumor efficacy ^[1].

HY-170432

PARP1-IN-34	PARP	Cancer
PARP1-IN-34 (compound 30) is a selective *PARP1* inhibitor with an IC₅₀ of 0.32 nM. PARP1-IN-34 is a subnanomolar PARP1 inhibitor with >1000-fold selectivity against *PARP2* with an IC₅₀ of 326 nM. PARP1-IN-34 shows antitumor efficacy_[1].

HY-173597

ZINC43120769	PARP	Cancer
ZINC43120769 is a *PARP1* inhibitor. ZINC43120769 can be used in prostate cancer (PC) research ^[1].

HY-U00223

WD2000-012547	PARP	Cancer
WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pK_i of 8.221.

HY-160417

PARP1-IN-19	PARP	Cancer
PARP1-IN-19 is a *PARP1* inhibitor with antitumor effects (CN107955001A; Embodiment 3) ^[1].

HY-139879

PARP1-IN-6	PARP	Cancer
PARP1-IN-6 is a dual *tubulin/PARP-1* inhibitor with IC₅₀ values of 0.94 and 0.48 μM, respectively.

HY-159612

PARP1-IN-28	PARP	Cancer
PARP1-IN-28 (compound 1) is a *PARP1* inhibitor. PARP1-IN-28 can be used in the study of cancer ^[1].

HY-108238

BSI-401	PARP	Cancer
BSI-401 is an orally active *PARP-1* inhibitor. BSI-401 alone and in synergism with Oxaliplatin (HY-17371) inhibits pancreatic cancer ^[1].

HY-162114

PARP1-IN-18	PARP	Cancer
PARP1-IN-18 (compound 25) is a potent *PARP1* inhibitor with an IC₅₀ value of 2.7 nM. PARP1-IN-18 has anticancer effects ^[1].

HY-174836

ZINC000081009201	PARP	Cancer
ZINC000081009201 is a potent poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with an IC₅₀ value of 1.4767 μM. ZINC000081009201 is promising for research of triple-negative breast cancer (TNBC) ^[1].

HY-164757

PARP-1-IN-32	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
PARP-1-IN-32 (compound 15) is a poly (ADPribose) polymerase-1 (PARP-1) inhibitor. PARP-1-IN-32 can be used in cancer research ^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PARP1+inhibitor

Inhibitors & Agonists

NaturalProducts

Natural
Products